How Pacific Biosciences Beat Expectations in Q4

1 min read

Pacific Biosciences of California (NASDAQ: PACB) no doubt made many investors happy in 2020, as its shares more than quintupled in value. The genetic sequencing systems stock is off to a great start in 2021 as well, with a year-to-date gain of 80%. 

The good times should keep rolling for PacBio. The company announced its fourth-quarter results after the market closed on Wednesday. Here are the highlights from PacBio’s Q4 update.

Image Source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Moelis & Company (MC) Q4 2020 Earnings Call Transcript

Next Story

Why I’m Not Too Worried About Weyerhaeuser’s Earnings Miss

Latest from Blog